Calypte Only Company with Full Menu of Tests.

           warrants to purchase our common stock at $0.50 per share issued in
           conjunction therewith;

     o     4,002,800 shares of our common stock, including 1,250,000 shares
           that have been previously issued to a selling security holder in
           connection with an aggregate $1,488,000 PIPE transaction at $0.40
           per share, and an additional 2,752,800 shares underlying warrants to
           purchase our common stock at $0.50 per share issued in conjunction
           therewith;

     o     3,100,801 shares of our common stock previously issued to a selling
           security holder upon the conversion of an aggregate principal amount
           of $800,072 of our 10% convertible debentures, including accrued
           interest, extension fees and other amounts;

     o     1,275,000 shares of our common stock underlying warrants issued to
           selling security holders in connection with a $10,000,000 5%
           Promissory Note Commitment Agreement and subsequent amendments
           thereof;

     o     1,172,205 shares of our common stock previously issued to a selling
           security holder in connection with a License Agreement and
           Technology Transfer Agreement (the "License Agreement");

     o     641,710 shares of our common stock that may be issued to selling
           security holders upon the conversion of the remaining $60,000
           aggregate principal amount of our 12% convertible debentures
           including accrued interest and other amounts;

     o     528,794 shares of our common stock underlying warrants or other
           agreements between us and certain selling security holders in
           connection with which we have obtained goods and services; and

     o     100,000 shares of our common stock underlying a warrant issued to a
           selling security holder as additional consideration in a convertible
           debenture transaction.

                                       consulting contracts. All of the shares
                                       offered by this Prospectus are being
                                       sold by the selling security holders

Risk                                    factors The shares involve a high degree
                                       of risk. Investors should carefully
                                       consider the information set forth under
                                       "RISK FACTORS" beginning on page 5.

Use of proceeds                         We will not receive any proceeds from
                                       the sale of our common stock offered
                                       through this Prospectus by the selling
                                       security holders. All proceeds from the
                                       sale of our common stock sold under this
                                       Prospectus will go to the selling
                                       security holders. We will, however,
                                       receive an aggregate of up to $6,889,514
                                       if the selling stockholders exercise all
                                       of their warrants to purchase common
                                       stock. We would expect to use any such
                                       proceeds for general corporate purposes.

Determination of offering price         This Prospectus may be used from time to
                                       time by the selling shareholders who
                                       offer our common stock in transactions
                                       (which may include block transactions)
                                       at prevailing market prices at the time
                                       of sale, at prices related to the
                                       prevailing market prices, or at other
                                       negotiated prices. The selling
                                       shareholders will act independently in
                                       determining the offering price of each
                                       sale.

Trading symbol for our common stock     HIV




PS: Wir haben noch einen ernst zu nehmenden Investor  ; ) mehr nicht

Gruß

C.O